(LMAT) LeMaitre Vascular - Ratings and Ratios
Allografts, Catheters, Patches, Grafts, Shunts
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.96% |
| Yield on Cost 5y | 2.13% |
| Yield CAGR 5y | 13.92% |
| Payout Consistency | 100.0% |
| Payout Ratio | 34.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 34.0% |
| Value at Risk 5%th | 51.4% |
| Relative Tail Risk | -8.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.66 |
| Alpha | -33.71 |
| CAGR/Max DD | 0.66 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.488 |
| Beta | 0.657 |
| Beta Downside | 0.664 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.32% |
| Mean DD | 10.88% |
| Median DD | 9.08% |
Description: LMAT LeMaitre Vascular November 11, 2025
LeMaitre Vascular, Inc. (NASDAQ: LMAT) designs, manufactures, and sells a broad suite of vascular-surgery devices-including allograft tissue grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, and a range of biologic and biosynthetic grafts-across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The product lineup also covers specialty items such as radiopaque tape, valvulotomes, and titanium-clip closure systems, and the company provides cryopreservation services for human cadaver tissue.
Founded in 1983 (originally Vascutech) and headquartered in Burlington, Massachusetts, LeMaitre reaches customers through a direct sales force complemented by regional distributors. Its biologic portfolio includes the ArteGraft bovine carotid artery for dialysis access, XenoSure and VascuCel/CardioCel patches for vessel and cardiac repair, and LifeSpan ePTFE grafts for lower-extremity bypasses, positioning the firm in high-growth niches such as peripheral artery disease (PAD) treatment and dialysis-access surgery.
According to the FY 2023 Form 10-K, LMAT generated roughly $120 million in revenue, with a 7 % year-over-year increase driven largely by rising demand for minimally invasive vascular interventions and an expanding global dialysis-patient base. The company’s R&D spend of about $12 million (≈10 % of revenue) reflects the broader health-care equipment sector’s focus on innovative, biologic-based solutions, while macro-drivers such as an aging population and higher prevalence of diabetes are expected to sustain long-term growth in vascular-device demand.
For a deeper, data-driven look at LMAT’s valuation and peer metrics, the ValueRay platform offers a concise, analytical snapshot worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (53.3m TTM) > 0 and > 6% of Revenue (6% = 14.5m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 2.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 173.8% (prev 92.84%; Δ 81.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 73.3m > Net Income 53.3m (YES >=105%, WARN >=100%) |
| Net Debt (160.1m) to EBITDA (86.7m) ratio: 1.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 13.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (24.4m) change vs 12m ago 6.81% (target <= -2.0% for YES) |
| Gross Margin 70.97% (prev 68.34%; Δ 2.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.40% (prev 56.50%; Δ -7.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 18.69 (EBITDA TTM 86.7m / Interest Expense TTM 4.09m) >= 6 (WARN >= 3) |
Altman Z'' 7.41
| (A) 0.70 = (Total Current Assets 452.0m - Total Current Liabilities 33.3m) / Total Assets 598.1m |
| (B) 0.29 = Retained Earnings (Balance) 173.7m / Total Assets 598.1m |
| (C) 0.16 = EBIT TTM 76.4m / Avg Total Assets 487.5m |
| (D) 0.78 = Book Value of Equity 171.0m / Total Liabilities 219.1m |
| Total Rating: 7.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.70
| 1. Piotroski 6.0pt |
| 2. FCF Yield 3.60% |
| 3. FCF Margin 27.49% |
| 4. Debt/Equity 0.49 |
| 5. Debt/Ebitda 1.85 |
| 6. ROIC - WACC (= 3.44)% |
| 7. RoE 14.96% |
| 8. Rev. Trend 96.67% |
| 9. EPS Trend 90.99% |
What is the price of LMAT shares?
Over the past week, the price has changed by -3.73%, over one month by -7.28%, over three months by -12.30% and over the past year by -20.19%.
Is LMAT a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LMAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.3 | 25.1% |
| Analysts Target Price | 104.3 | 25.1% |
| ValueRay Target Price | 89.3 | 7.1% |
LMAT Fundamental Data Overview November 25, 2025
P/E Trailing = 37.9009
P/E Forward = 33.3333
P/S = 8.2817
P/B = 5.2643
P/EG = 1.9032
Beta = 0.664
Revenue TTM = 240.9m USD
EBIT TTM = 76.4m USD
EBITDA TTM = 86.7m USD
Long Term Debt = 168.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 185.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 160.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.84b USD (1.99b + Debt 185.6m - CCE 343.1m)
Interest Coverage Ratio = 18.69 (Ebit TTM 76.4m / Interest Expense TTM 4.09m)
FCF Yield = 3.60% (FCF TTM 66.2m / Enterprise Value 1.84b)
FCF Margin = 27.49% (FCF TTM 66.2m / Revenue TTM 240.9m)
Net Margin = 22.14% (Net Income TTM 53.3m / Revenue TTM 240.9m)
Gross Margin = 70.97% ((Revenue TTM 240.9m - Cost of Revenue TTM 69.9m) / Revenue TTM)
Gross Margin QoQ = 75.28% (prev 70.02%)
Tobins Q-Ratio = 3.07 (Enterprise Value 1.84b / Total Assets 598.1m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.6m)
Taxrate = 23.09% (5.21m / 22.6m)
NOPAT = 58.8m (EBIT 76.4m * (1 - 23.09%))
Current Ratio = 13.58 (Total Current Assets 452.0m / Total Current Liabilities 33.3m)
Debt / Equity = 0.49 (Debt 185.6m / totalStockholderEquity, last quarter 378.9m)
Debt / EBITDA = 1.85 (Net Debt 160.1m / EBITDA 86.7m)
Debt / FCF = 2.42 (Net Debt 160.1m / FCF TTM 66.2m)
Total Stockholder Equity = 356.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.92% (Net Income 53.3m / Total Assets 598.1m)
RoE = 14.96% (Net Income TTM 53.3m / Total Stockholder Equity 356.6m)
RoCE = 14.56% (EBIT 76.4m / Capital Employed (Equity 356.6m + L.T.Debt 168.4m))
RoIC = 11.21% (NOPAT 58.8m / Invested Capital 524.7m)
WACC = 7.77% (E(1.99b)/V(2.18b) * Re(8.44%) + D(185.6m)/V(2.18b) * Rd(0.70%) * (1-Tc(0.23)))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.21%
[DCF Debug] Terminal Value 80.17% ; FCFE base≈53.1m ; Y1≈65.5m ; Y5≈111.8m
Fair Price DCF = 77.64 (DCF Value 1.76b / Shares Outstanding 22.7m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.99 | EPS CAGR: 30.05% | SUE: 4.0 | # QB: 2
Revenue Correlation: 96.67 | Revenue CAGR: 12.31% | SUE: -1.10 | # QB: 0
Additional Sources for LMAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle